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Surgical bypass vs endovascular treatment for
patients with supra-aortic arterial occlusive disease
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Ga-Yeon Lee, MD,b Duk-Kyung Kim, MD,b Keonha Kim, MD,c and Kiick Sung, MD,d Seoul, Korea
Objective: This study compared treatment outcomes of patients with supra-aortic arterial (SAA) occlusive disease due to
Takayasu arteritis (TA) treated with bypass surgery or endovascular treatment.
Methods: All patients diagnosed with TA from September 1994 to November 2010 were identified using the hospital
database. This retrospective study included 21 TA patients who underwent endovascular or surgical intervention due to
SAA lesions and four patients whowere referred from other hospitals after endovascular treatment of SAA lesions. Fifteen
arterial lesions in 10 patients were treated with an endovascular technique, and 24 arteries in 15 patients were
reconstructed using bypass surgery. We performed endovascular intervention for short (<5 cm) stenotic lesions and
bypass surgery for longer occlusive lesions. After surgical or endovascular intervention, anti-inflammatory medication
(steroids, methotrexate, or azathioprine, or both) was given to 12 patients (48%) with evidence of disease activity for a
mean of 4.4  4.5 months (median, 2.6; range, 1-15 months). We reviewed and compared demographic and clinical
features, lesion characteristics, indications for treatment, and treatment results between the bypass surgery and
endovascular treatment groups. To evaluate the treatment results, we assessed the patency of reconstructed arteries,
recurrent symptoms, and complications associated with treatment.
Results: During the 194-month study period, 9.6% of TA patients with SAA lesions required bypass surgery or
endovascular treatment. The typical indication for treatment was brain ischemic symptoms. Two patients were neuro-
logically asymptomatic but had cervical artery occlusion in conjunction with an aortic arch aneurysm or symptomatic
aortic regurgitation. During a mean follow-up of 39.4 44.4 months (median, 23.2; range, 0.5-178 months), restenosis
(>50%) or occlusion of the reconstructed arteries was observed in eight of 15 arteries (53.3%) in the endovascular
treatment group vs three of 24 (12.5%) in the bypass surgery group (P  .01; Fisher exact test). More serious
complications, such as intracerebral hemorrhage (n  2) due to cerebral hyperperfusion syndrome or cardiac tamponade
developed in the surgical bypass group. No operative deaths occurred in either group.
Conclusions: Surgical or endovascular interventions were required in one of 10 TA patients with SAA occlusive lesions.
Arteries reconstructed after surgical bypass had superior patency to those reconstructed by endovascular treatment.
However, bypass surgery was more likely than endovascular treatment to be accompanied by serious early postoperative
complications. ( J Vasc Surg 2012;55:693-700.)
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iTakayasu arteritis (TA) is a rare form of chronic vascu-
litis that characteristically affects the aorta and its primary
branches and is more frequently found in young women.
The reported frequency of supra-aortic arterial (SAA, eg,
innominate, subclavian, carotid, and vertebral) involve-
ment in TA patients can vary due to different definitions of
arterial involvement or the type of imaging modality used
to diagnose TA. Previous studies reported that 31% to 54%
of TA patients had SAA lesions on angiographic examina-
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doi:10.1016/j.jvs.2011.09.051ion.1,2 Clinical features of SAA lesions range from asymp-
omatic to major stroke.3,4 Most TA patients with SAA
cclusive disease seek medical help due to symptoms asso-
iated with brain hypoperfusion, which can be complicated
y coexisting severe hypertension. A study reported that
7% of TA patients developed stroke or transient ischemic
ttack (TIA) and that stroke accounted for 9.5% of deaths
n TA patients.5
Although not all patients show distinct stages, TA is
haracterized by three stages: active inflammation with
onstitutional symptoms, vascular inflammation with
ymptoms of vessel pain or tenderness, and vessel fibrosis
r degeneration presenting as ischemic symptoms or
neurysm.
TA is primarily treated by pharmacologic therapy, but
urgical or endovascular treatment may be required to treat
rgan ischemia, renovascular hypertension, or aneurysmal
esions in late-stage TA. However, an evidence-based con-
ensus regarding indications for surgical or endovascular
ntervention and optimal treatment options for patients
ith TA involving SAA lesions are lacking.
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March 2012694 Kim et alAlthough surgical bypass is considered the standard
form of treatment for TA patients with irreversible, symp-
tomatic SAA lesions, endovascular treatment has been at-
tempted, with inconsistent treatment results reported.6-9
Furthermore, previous reports of endovascular treatment
of SAA lesions in TA patients are limited by the small
number of patients evaluated, differences in lesion charac-
teristics and locations, the frequency of active disease at the
time of intervention, the type of endovascular technique
used (eg, use of a stent), and differences in the postproce-
dural medical treatment. In the present study, we com-
pared the efficacies of surgical bypass and endovascular
treatment in TA patients with SAA lesions.
METHODS
A database of all consecutive TA patients treated at one
academic institution in Seoul, Korea, between September
1994 and November 2010, was reviewed retrospectively.
Approval was obtained from our Institutional Review
Board for a retrospective review of patients’ medical records
and images.
TA was diagnosed based mainly on the American Col-
lege of Rheumatology diagnostic criteria (Table I).10 This
retrospective study included 21 TA patients with SAA
lesions who underwent surgical or endovascular interven-
tion to treat the SAA lesions in our hospital and four who
were referred to our hospital from other hospitals after
endovascular treatment of SAA lesions. Preoperative clini-
cal features, lesion characteristics, methods of surgical or
endovascular treatment, and early and late postoperative
outcomes were reviewed retrospectively.
To assess TA disease activity, erythrocyte sedimenta-
tion rate (ESR) and C-reactive protein (CRP) level were
used as biologic markers of inflammation along with
contrast-enhanced computed tomography (CT) or mag-
netic resonance imaging (MRI). Active-stage TA was de-
fined as one or more of the following: elevated ESR (21
mm/h) or CRP (0.9 mg/dL), arterial wall thickening
(2 mm) with wall enhancement on contrast-enhanced
MRI or CT scans, or the presence of systemic symptoms or
carotid tenderness.
We attempted surgical or endovascular intervention in the
Table I. The American College of Rheumatology 1990
criteria for the diagnosis of Takayasu arteritisa
Criteria and definition
● Age at disease onset 40 years
● Limb claudication
● Decreased brachial artery pulse
● Difference in systolic blood pressure between arms 10 mm
Hg
● Bruit over the subclavian arteries or the aorta
● Arteriographic evidence of narrowing or occlusion of the en-
tire aorta its primary branches, or large arteries in the proximal
upper or lower extremities
aThe presence of  three of these six criteria demonstrated a sensitivity of
90.5% and a specificity of 97.8%.inactive stage after ESR and CRP values had returned to values rhat were within normal reference ranges. However, two of 10
atients (20%) who underwent endovascular intervention and
our of 15 (26.6%) who underwent a surgical bypass operation
nderwent operations when they had an elevated ESR (n 4;
ean, 59.540.5; range, 34-120mm/h)orCRP level (n2;
ean, 8.3; range, 1.62-14.98 mg/dL) because of emergency
ircumstances. TA patients with SAA lesions and brain ischemic
ymptomswere considered tobe candidates for surgical or endo-
ascular intervention. Two patients who underwent cervical ar-
ery bypasses in conjunction with aortic valve or aortic arch
eplacementwereneurologically asymptomaticbefore thebypass
urgery.
Endovascular treatment was chosen for symptomatic
atients with short (5 cm) stenotic SAA lesions. Multi-
evel, long occlusive lesions of cervical arteries were treated
ith surgical bypass (Fig).
The primary endovascular treatment was percutaneous
ransluminal angioplasty (PTA) with a balloon. Bare-metal
tenting was reserved as a rescue procedure in cases of
omplication during balloon angioplasty. We performed
even PTAs in five patients. Seven patients underwent
lacement of eight balloon-expandable stents, including
MART (Cordis Corp, Bridgewater, NJ), Palmaz (Cordis
orp), BX Velocity (Cordis Corp), or Protege GPS (ev3
ndovascular, Inc, Plymouth, Minn).
Lesions targeted by endovascular treatment were dis-
ributed in the common carotid artery in three (PTA in one,
tenting in two), internal carotid artery in one (stenting),
xternal carotid artery in one (PTA), vertebral artery in two
PTA in one, stenting in one), and subclavian artery in eight
PTA in four, stenting in four). We attempted endovascular
reatment for a short, stenotic, ostial lesion of the subcla-
ian artery. Vertebral artery interventions were performed
n the first part of the artery before it ran into the transverse
rocess foramens.
Our preferred surgical bypass procedure for the TA
atient with SAA lesions was ascending aorta origin bypass,
ncluding aortocarotid bypass in 13 (aortobicarotid in five;
ortounicarotid in eight), innominate interposition in two,
nd aortoaxillary bypass in two. The bypass conduit was
xternally supported polytetrafluoroethylene grafts in 13
atients and autogenous saphenous vein grafts in two. For
he SAA reconstructions, two coronary artery bypass graft-
ng procedures, one aortic valve replacement, and one total
ortic arch replacement, were performed concomitantly.
After surgical or endovascular treatment, 12 patients
48%) who had one or more signs of disease activity were
iven anti-inflammatory medication (steroids, methotrex-
te, azathioprine, or a combination) for a mean duration of
.4  4.5 months (median, 2.6 months; range, 1-15
onths). Antiplatelet agents were prescribed for all patients
xcept those with postoperative intracerebral hemorrhage.
To assess postoperative results, we investigated the pa-
encyof the treated arteries or bypass grafts, recurrent or newly
ccurring neurologic symptoms, and early (30 days) and
ate complications related to surgical or endovascular treat-
ent. To examine the patency of reconstructed arteries, we
outinely examined patients at 6-month intervals in the out-
r
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Volume 55, Number 3 Kim et al 695patient clinic after hospital discharge using CT (LightSpeed
VCT, General Electric, Waukesha, Wisc) or MR angiography
(Achieva 3.0T; Philips Medical Systems, Best, The Nether-
lands) for patients who underwent ascending aorta-based
bypass surgery or endovascular treatment of intrathoracic
arteries.We used duplex ultrasound imaging (iU 22 [Phillips]
Fig. Images are shown for endovascular treatment and
supra-aortic arteries.Top (left), Aortic arch angiogram in
of the right subclavian artery and multiple, diffuse steno
arteries. Top (right), After balloon angioplasty of the r
computed tomography angiogram in a 45-year-old wom
lesions at the right subclavian arteries. Bottom (right)
bypasses with prosthetic grafts.and Antares [Siemens AG,Munich, Germany]) to assess arte- tial patency in patients who had undergone endovascular
reatment of cervical arterial lesions.
ESULTS
From September 1994 to November 2010, 232 pa-
cal bypass for patients with Takayasu arteritis affecting
year-old woman shows a short-segment stenosis (arrow)
r occlusive lesions in the carotid, vertebral, and axillary
subclavian artery stenosis. Bottom (left), Preoperative
ows multiple occlusive cervical arteries and aneurysmal
r ascending aorta-to-bilateral carotid and right axillarysurgi
a 36-
tic o
ight
an sh
, Afteients with TA were identified, among whom 218 (94%)
3 (1.4) 0 20 (9.2)
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dConcomitant one carotid and one subclavian artery reconstructions in a
patient who underwent aortic arch replacement were included.
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March 2012696 Kim et alhad SAA lesions evidenced by wall thickening with or
without stenosis/occlusion or ectatic/aneurysmal lesions
on CT scans, MRI, or ultrasound imaging. Table II shows
the frequencies of SAA lesions in TA patients. When arterial
wall thickening was included as a type of arterial lesion, the
most affected arteries were the common carotid artery
(right, 70.6%; left, 78%; both, 40%), followed by the sub-
clavian (right, 59.1%; left, 72%; both, 22%), the innominate
(49.1%), and the internal carotid arteries (right, 26.6%; left,
30.3%; both, 9.2%). However, arterial occlusion was most
common in the left subclavian artery, followed by the left
common carotid and right subclavian arteries. Ectatic or
aneurysmal change occurred most frequently in the innom-
inate arteries, and stenotic lesions weremost frequent in the
common carotid arteries (Table II).
Among all TA patients, 21 (9.1%), or 9.6% of TA
patients with SAA lesions, underwent surgical or endovas-
cular treatment at our hospital. Table III lists the demo-
graphic and clinical features of the 25 patients who under-
went surgical or endovascular treatment. CT angiography
(n  19), MR angiography (n  11), and duplex ultra-
sound (n  22) follow-up images were available in 21
patients (84%) who were monitored up for a mean of 39.4
44.4 months (median, 23.2; range, 0.5-178 months). The
treatment procedures and follow-up results are reported in
Table IV. We experienced poor results for endovascular
treatment (four PTAs and four stentings) of orifice lesions
of the subclavian artery, including initial technical failures
in two (25%) and occlusion or restenosis in four (50%)
patients during the follow-up period.
In a patient complaining of episodes of severe pos-
tural dizziness and visual dimness due to bilateral inter-
nal carotid and right external carotid occlusive lesions,
we performed left internal carotid artery stenting to
improve this patient’s brain ischemic symptoms and PTA
of the right external carotid artery to improve visual
dimness by increasing blood flow to the ophthalmic and
retinal arteries. The patient’s right eye symptoms im-
Table II. Distribution of arterial lesions affecting the supr
Affected artery Wall thickening Stenosis
Innominate 55 (25.2) 34 (15.6
Common carotid
Right 49 (22.5) 77 (35.3
Left 41 (18.8) 75 (34.4
Both 26 (11.9) 45 (20.6
Subclavian
Right 28 (12.8) 53 (24.3
Left 15 (6.9) 59 (27)
Both 4 (1.8) 18 (8.3)
Internal carotid
Right 20 (9.2) 27 (12.4
Left 12 (5.5) 42 (19.3
Both 6 (2.8) 11 (5)a-aortic arteries in 218 patients
Arterial lesions, No. (%)
Occlusion
Ectatic or
aneurysmal Subtotal
) 8 (3.7) 10 (4.6) 107 (49.1)
) 24 (11) 4 (1.8) 154 (70.6)
) 51 (23.4) 3 (1.4) 170 (78)
) 16 (7.3) 0 87 (40)
) 37 (17) 11 (5) 129 (59.1)
82 (37.6) 1 (0.5) 157 (72)
25 (11.5) 1 (0.5) 48 (22)
) 11 (5) 0 58 (26.6)
) 12 (5.5) 1 (0.4) 66 (30.3)proved after endovascular treatment. During endovascu-able III. Demographic and clinical features of 25
atients who underwent surgical or endovascular
reatment of supra-aortic arterial lesions
eaturea
Treatment method
Bypass surgery Endovascular
atients 15 10
ge, years
At the diagnosis 34  13 34  11
At symptom onset 29  13 32  11
emale 15 (100) 7 (70)
ctive stageb
At the initial
presentation
12 (80) 8 (80)
At the time of
intervention
4 (26.6) 1 (10)
linical manifestation 15 (100) 9 (90)
pisodic visual dimness 12 (80) 5 (50)
ostural dizziness 9 (60) 6 (60)
pisode of syncope 4 (26.7) 0
ransient ischemic attack 3 (20) 3 (30)
inor stroke 0 2 (20)
ymptom of AR 1c(6.7) 0
ortic arch aneurysm 1c(6.7) 0
reated arteries 24 15
Innominate artery 2 0
Carotid artery 19d 5
Subclavian artery 3d 8
Vertebral artery 0 2
R, Aortic regurgitation.
Continuous data are presented as mean  standard deviation; categoric
ata as number (%).
Active stage was defined as one finding among elevated erythrocyte
edimentation rate (21 mm/h) or C-reactive protein (0.9 mg/dL),
rterial wall thickening (2 mm) with arterial wall enhancement on con-
rast-enhanced magnetic resonance imaging or computed tomography scan,
r presence of systemic symptom or carotid tenderness.
Symptom of aortic regurgitation or signs of impending rupture of aortic
rch were present but lacked brain ischemic symptoms.
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Volume 55, Number 3 Kim et al 697lar treatment, two subclavian stentings were technically
unsuccessful, and one carotid dissection developed as a
procedural complication.
Restenosis (50%) or occlusion developed in eight
of 15 arteries (53.3%) after endovascular treatment com-
Table IV. Surgical or endovascular procedures and follow
Patient
Sex Age TreatmentTreatment
Bypass surgery
1 F 38 Aorta-bicarotid bypa
2 F 69 Innominate
interposition
3 F 26 Aorta-bicarotid bypa
4 F 36 Innominate
interposition
Aorta-CCA bypass,
AVR
5 F 27 Aorta-unicarotid
bypass
6 F 33 Total arch
replacement
Aorta-subclavian
bypass
Aorta-carotid bypass
7 F 29 Aorta-bicarotid bypa
8 F 15 Aorta-unicarotid
bypass
9 F 44 Aorta-bicarotid bypa
10 F 66 Aorta-unicarotid
bypass
11 F 18 Aorta-unicarotid
bypass
12 F 56 Aorta-unicarotid 
CABG
13 F 57 Aorta-unicarotid 
CABG
14 F 45 Aorta-bicarotid bypa

Aorta-axillary bypass
15 F 39 Aorta-unicarotid
Aorta-axillary bypass
Endovascular
16 F 20 Carotid PTA
17 M 44 Subclavian PTA
Vertebral PTA
46 Carotid stenting
48 Carotid stenting
Subclavian PTA
18 F 31 Subclavian stenting
19 F 55 Subclavian stenting
(fail)
20 F 22 Subclavian PTA
21 F 36 Subclavian PTA
22 F 25 Vertebral stenting
23 F 33 Subclavian stent (fail
24 M 46 Internal carotid
stenting
External carotid PTA
25 M 44 Subclavian stenting
AVR, Aortic valve replacement; CABG, coronary artery bypass grafting, CC
applicable; PTA, percutaneous transluminal angioplasty (balloon).pared with three of 24 arteries (12.5%) after surgical bypass FP  .01 by Fisher exact test); however, the differences in
he frequency of grafts or arterial restenosis (50%) or
cclusion between patients with active-stage (one of seven
rteries [14.3%]) and inactive-stage disease (10 of 32 arter-
es [31.3%]) were not statistically significant (P  .649 by
esults
Follow-up results
Duration
Patency Recurrent symptoms(months)
95 Patent None
LTF NA None
89 Patent None
13 Patent None
13 Patent None
65 Patent None
36
36 Patent None
36 Patent None
27 Right, occluded None
36 Left, patent None
31 Patent None
20 Patent None
16 Occluded None
37 Restenosis None
13 Patent None
13 Patent None
1 Patent None
1 Patent None
0.5 Patent None
0.5 Patent None
44 Restenosis None
31 Restenosis Visual dimness
31 Restenosis Visual dimness
19 Restenosis Visual dimness
99 Restenosis Blindness
99 Patent Dizziness
32 Occluded None
NA NA None
120 Restenosis None
152 Occluded Visual dimness
178 Patent Dizziness
NA NA None
LTF NA None
LTF NA None
5 Patent None
mmon carotid artery; F, female; LTF, lost to follow-up; M, male; NA, not-up r
ss
ss
ss
ss
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)isher exact test).
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March 2012698 Kim et alTable V reports early (30 days) and late complications
after surgical and endovascular treatment. After bypass
surgery, two cases of cerebral hyperperfusion syndrome,
one case of cardiac tamponade, and one case of severe
hemodynamic instability developed. The two patients who
experienced cerebral hyperperfusion syndrome included a
patient with bilateral common carotid occlusion who un-
derwent an aortobicarotid bypass and another patient with
bilateral common carotid and left subclavian artery occlu-
sions who underwent combined aortounicarotid and left
axillary bypasses to improve cerebral and vertebral artery
blood flow. Intracerebral hemorrhage in these patients
occurred on postoperative days 6 and 7, respectively. To
treat surgical complications, one of the two patients with
intracerebral hemorrhage required surgical removal of an
intracerebral hematoma and a patient complicated with
cardiac tamponade required reoperation to control the
bleeding. For a patient who showed severe hemodynamic
instability during the aortocarotid bypass, we used an ex-
tracorporeal membrane oxygenator for 24 hours postoper-
atively until vital signs were stabilized. No surgical deaths
occurred.
No recurrent ischemic symptoms developed after by-
pass surgery, although ischemic symptoms did develop in
40% of patients after endovascular treatment. During the
follow-up period, one patient (4%) died of a coexisting
pulmonary disease.
DISCUSSION
The characteristics of SAA lesions due to TA (eg,
diffuse, long, thick fibrosis of arterial wall) are different
from those of atherosclerotic SAA lesions, thus the clinical
features and prognosis of TA patients may differ from those
of patients with atherosclerotic SAA lesions. The clinical
manifestations of SAA lesions in TA patients can cause
global hypoperfusion of the brain rather than cerebral
infarction due to embolic causes.
Liang et al11 reported a high failure rate for endovas-
Table V. Early (30 days) and late complications after su
Takayasu arteritis involving supra-aortic arteries
Complication
Early (30 days)
Cerebral hyperperfusion syndrome with intracerebral hemorrha
Cardiac tamponade
Severe bradycardia with hemodynamic instability
Technical failure
Arterial dissection
Late
Restenosis (50% of diameter)
Graft occlusion
Death
NA, Not applicable.
aOne patient died of a coexisting pulmonary disease.cular revascularization procedures to treat various arterial tesions in TA patients. Nevertheless, many have attempted
ndovascular techniques to treat arterial lesions due to TA,
ith heterogeneous outcomes reported.12-14 Tyagi et al15
eported good early-term and intermediate-term results
fter carotid PTA or stent placement in TA patients. Min et
l16 also reported a procedural success rate of 90% and a
estenosis rate of only 17% during a mean follow-up of 2
ears after endovascular treatment (19 PTAs and 39 stent
nsertions) of patients with TA affecting various arteries. It
s hard to generalize the results of endovascular treat-
ent of SAAs in TA patients because of the limited
umber of patients examined, as well as differences in the
esions examined (length, location, ostial vs nonostial,
isease activity, multiplicity of lesions), procedures (eg,
he stent use, number of stents used), and medical
herapy after treatment.
Recently, Qureshi et al17 reported a lower restenosis
ate after the use of stent grafts rather than bare stents for
A patients with occlusive lesions in the abdominal aorta,
enal, visceral, and SAAs. According to these authors, the
se of stent grafts over uncovered stents can mitigate the
isk of in-stent restenosis and occlusion. Although several
uthors reported a high initial success rate after endovascu-
ar treatment of SAA lesions in TA patients, restenosis
emains a major concern.18
Surgical reconstruction is performed to improve brain
schemic symptoms or to prevent stroke in patients with
AAs caused by TA.19 Liang et al11 assessed long-term
esults after surgical bypass and endovascular treatment of
atients with TA. They reported endovascular revascular-
zation, especially after using stents, was associated with
igher failure rates in patients with TA despite the short-
erm benefits provided by this approach. Among surgical
rocedures, patch angioplasty or endarterectomy was asso-
iated with higher failure rates than bypass surgery.
Our endovascular treatment results are consistent with
revious studies that reported less-favorable outcomes for
ndovascular treatment vs bypass surgery. Although the
l bypass and endovascular treatment for patients with
Bypass surgery, No. (%)
Endovascular treatment,
No. (%)
Patients Arteries Patients Arteries
(n  15) (n  24) (n  10) (n  15)
2 (13.3) NA 0 0
1 (6.7) NA NA NA
1 (6.7) NA 0 0
0 0 2 (20.0) 2 (13.3)
0 0 1 (10.0) 1 (6.7)
1 (6.7) 1 (4.2) 3 (30.0) 6 (40.0)
2 (13.3) 2 (8.3) 2 (20.0) 2 (13.3)
1 (6.7)a NA 0 0rgica
geechnical success rate of endovascular treatment was 87% in
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Volume 55, Number 3 Kim et al 699our series, eight of 15 arteries (53.4%) treated by endovas-
cular interventions were occluded or developed restenosis
(50%) during the mean follow-up of 53.3  59 months
(median, 31.4; range, 1.8-178 months). Among patients
whose treated artery showed occlusion or restenosis, brain
ischemic symptoms developed in three patients (30%).
Among 24 SAAs in 15 patients who were treated by
bypass surgery, we found one restenosis (50%) and two
graft occlusions during the follow-up period. Compared
with the endovascular treatment group, the frequency of
restenosis or graft occlusion was significantly lower after
surgical bypass and was not associated with recurrent brain
ischemic symptoms.
However, intracerebral hemorrhage due to cerebral
hyperperfusion syndrome was observed in two patients
(13.3%), and severe hemodynamic instability developed in
one patient during or after bypass surgery. Cerebral hyper-
perfusion syndrome developed 6 and 7 days after aortoca-
rotid bypass, respectively, with concurrent episodes of
poorly controlled severe hypertension (190 mm Hg of
systolic blood pressure), resulting in intracerebral hemor-
rhage. One patient recovered with minor sequelae after
nonsurgical treatment, but the other patient remains in a
vegetative state after surgical removal of an intracerebral
hematoma.
To avoid postoperative cerebral hyperperfusion syn-
drome, treatment of coexisting hypertension is important.
When a TA patient presents with SAA and renal arterial
lesions, we recommend treating the severe renovascular
hypertension before treating the SAA lesions. To avoid
cerebral hyperperfusion syndrome, we recommend unilat-
eral carotid reconstruction for patients with occlusions of
both common carotid arteries. This is also why we do not
perform a synchronous bilateral carotid endarterectomy for
a patient with bilateral critical carotid stenosis due to ath-
erosclerosis.
Some have claimed that surgical or endovascular inter-
ventions should be avoided during the acute inflammatory
stage of TA to avoid anastomotic dehiscence or restenosis.
According to Fields et al,20 performing surgery in patients
with active-stage TA increases the risk of early graft revision
and the progression of symptomatic disease in other arterial
beds. Park et al9 reported a lower restenosis rate when
vascular interventions were performed during the inactive
stage of TA and when postinterventional immunosuppres-
sive treatment was implemented. In addition to ESR or
serum CRP levels, various other serologic markers, includ-
ing serum cytokines, matrix metalloproteinases, and serum
amyloid A, have been reported to be biologic markers of
active TA.21-23
In current clinical practice, no single marker accurately
reflects the activity of TA. An autopsy study from India
reported that TA disease activity persists for a long time,
even in the absence of clinical or laboratory examinations.24
Takagi25 also described how steroids apparently suppress
serum inflammatory reactions but leave the pathologic
status of the arterial wall unchanged. Contrast-enhanced
CT and MRI or 18F-fluorodeoxyglucose positron-emission Womography was recently used to determine the presence of
cute inflammation in vessel walls for the diagnosis of large
essel vasculitis.26,27 However, in severely symptomatic TA
atients with SAA lesions, it is not always possible to
ostpone SAA reconstruction until biologic markers return
o normal.
Tada et al28 reported that they have been surgically
reating TA patients regardless of disease activity since the
980s. We performed endovascular interventions and sur-
ical bypasses during states of elevated ESR or CRP in 20%
nd 26.6% of patients, respectively, because these patients
equired urgent treatment. Postoperative anti-inflammatory
herapy was performed for all of these patients. After surgi-
al or endovascular interventions, we found no significant
ifferences in the frequency of restenosis (50%) or occlu-
ion (active stage in one of seven arteries [14.3%] vs inactive
tage in 10 of 32 arteries [31.3%]; P .649 by Fisher exact
est) between patients treated in the active (six [24%]) or
nactive (19 [76%]) stages. However, this nonsignificant
esult may have been due to a lack of statistical power
ecause of the small number of patients treated when they
ad active-stage disease.
Although our study was retrospective in design and the
atient volume was small, arteries repaired by surgical by-
ass showed better patency than those repaired by endo-
ascular treatment even though surgical bypasses were usu-
lly performed in patients with more advanced arterial
esions. Furthermore, compared with surgical bypass,
ymptom recurrence was more common in patients who
nderwent endovascular treatment.
Our findings are similar to those reported by AbuRahma
t al29 in a study of patients with atherosclerotic subclavian
rtery occlusive disease. They reported that the long-term
urability of arteries was better when surgical bypass surgery
as performed than after an endovascular procedure but that
ore perioperative complications occurred in the surgical
ypass group.
ONCLUSIONS
About 10% of TA patients with SAA lesions in this
tudy required surgical or endovascular treatment. Endo-
ascular treatment can be attempted as a less-invasive treat-
ent for short stenotic SAA lesions. However, this treat-
ent is associated with a higher risk of restenosis or
cclusion than bypass surgery, even after postoperative
nti-inflammatory treatment. Bypass surgery results in bet-
er artery patency when used to treat SAA lesions due to
A; however, the risk of serious early postoperative com-
lications should be considered.
We thank Nari Kim, RN, for her assistance in data
ollection.
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